Phase 1 / 2 Study of AGEN2034 in Advanced Tumors and Cervical Cancer
Status:
Active, not recruiting
Trial end date:
2022-05-14
Target enrollment:
Participant gender:
Summary
This is a 2-part trial: a Phase 1, open-label, dose-escalation study in subjects with
metastatic or locally advanced solid tumors, with a consecutive Phase 2 expansion to evaluate
efficacy in subjects with recurrent, unresectable, or metastatic (advanced) cervical cancer
that has progressed after a platinum-based treatment regimen.